107 related articles for article (PubMed ID: 10049697)
1. Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer.
Kleeff J; Maruyama H; Friess H; Büchler MW; Falb D; Korc M
Biochem Biophys Res Commun; 1999 Feb; 255(2):268-73. PubMed ID: 10049697
[TBL] [Abstract][Full Text] [Related]
2. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer.
Kleeff J; Ishiwata T; Maruyama H; Friess H; Truong P; Büchler MW; Falb D; Korc M
Oncogene; 1999 Sep; 18(39):5363-72. PubMed ID: 10498890
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest.
Nicolás FJ; Hill CS
Oncogene; 2003 Jun; 22(24):3698-711. PubMed ID: 12802277
[TBL] [Abstract][Full Text] [Related]
5. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
[TBL] [Abstract][Full Text] [Related]
6. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of transforming growth factor beta receptors in human pancreatic adenocarcinoma.
Venkatasubbarao K; Ahmed MM; Mohiuddin M; Swiderski C; Lee E; Gower WR; Salhab KF; McGrath P; Strodel W; Freeman JW
Anticancer Res; 2000; 20(1A):43-51. PubMed ID: 10769633
[TBL] [Abstract][Full Text] [Related]
8. Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma.
Liu X; Lee J; Cooley M; Bhogte E; Hartley S; Glick A
Cancer Res; 2003 Nov; 63(22):7760-8. PubMed ID: 14633701
[TBL] [Abstract][Full Text] [Related]
9. Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.
Peng B; Fleming JB; Breslin T; Grau AM; Fojioka S; Abbruzzese JL; Evans DB; Ayers D; Wathen K; Wu T; Robertson KD; Chiao PJ
Clin Cancer Res; 2002 Nov; 8(11):3628-38. PubMed ID: 12429655
[TBL] [Abstract][Full Text] [Related]
10. Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis.
Halder SK; Beauchamp RD; Datta PK
Exp Cell Res; 2005 Jul; 307(1):231-46. PubMed ID: 15922743
[TBL] [Abstract][Full Text] [Related]
11. Glypican-1 antisense transfection modulates TGF-beta-dependent signaling in Colo-357 pancreatic cancer cells.
Li J; Kleeff J; Kayed H; Felix K; Penzel R; Büchler MW; Korc M; Friess H
Biochem Biophys Res Commun; 2004 Aug; 320(4):1148-55. PubMed ID: 15249209
[TBL] [Abstract][Full Text] [Related]
12. A kunitz-type protease inhibitor bikunin disrupts ligand-induced oligomerization of receptors for transforming growth factor (TGF)-beta and subsequently suppresses TGF-beta signalings.
Yagyu T; Kobayashi H; Wakahara K; Matsuzaki H; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
FEBS Lett; 2004 Oct; 576(3):408-16. PubMed ID: 15498571
[TBL] [Abstract][Full Text] [Related]
13. Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer.
Arnold NB; Ketterer K; Kleeff J; Friess H; Büchler MW; Korc M
Cancer Res; 2004 May; 64(10):3599-606. PubMed ID: 15150118
[TBL] [Abstract][Full Text] [Related]
14. Smad expression in human atherosclerotic lesions: evidence for impaired TGF-beta/Smad signaling in smooth muscle cells of fibrofatty lesions.
Kalinina N; Agrotis A; Antropova Y; Ilyinskaya O; Smirnov V; Tararak E; Bobik A
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1391-6. PubMed ID: 15166010
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor-beta-induced inhibition of myogenesis is mediated through Smad pathway and is modulated by microtubule dynamic stability.
Zhu S; Goldschmidt-Clermont PJ; Dong C
Circ Res; 2004 Mar; 94(5):617-25. PubMed ID: 14739161
[TBL] [Abstract][Full Text] [Related]
16. TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.
Paterson IC; Davies M; Stone A; Huntley S; Smith E; Pring M; Eveson JW; Robinson CM; Parkinson EK; Prime SS
Oncogene; 2002 Feb; 21(10):1616-24. PubMed ID: 11896591
[TBL] [Abstract][Full Text] [Related]
17. Potential role of transforming growth factor beta1 in drug resistance of tumor cells.
Stoika R; Yakymovych M; Souchelnytskyi S; Yakymovych I
Acta Biochim Pol; 2003; 50(2):497-508. PubMed ID: 12833174
[TBL] [Abstract][Full Text] [Related]
18. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease.
Monteleone G; Kumberova A; Croft NM; McKenzie C; Steer HW; MacDonald TT
J Clin Invest; 2001 Aug; 108(4):601-9. PubMed ID: 11518734
[TBL] [Abstract][Full Text] [Related]
19. Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta.
Jazag A; Ijichi H; Kanai F; Imamura T; Guleng B; Ohta M; Imamura J; Tanaka Y; Tateishi K; Ikenoue T; Kawakami T; Arakawa Y; Miyagishi M; Taira K; Kawabe T; Omata M
Oncogene; 2005 Jan; 24(4):662-71. PubMed ID: 15592526
[TBL] [Abstract][Full Text] [Related]
20. Regulation of transforming growth factor-beta signaling.
Zhu HJ; Burgess AW
Mol Cell Biol Res Commun; 2001 Nov; 4(6):321-30. PubMed ID: 11703090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
